Suppr超能文献

葡萄糖脑苷脂酶活性调节神经元对病理性α-突触核蛋白损伤的易感性。

Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.

机构信息

Institute on Aging and Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Institute on Aging and Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Neuron. 2020 Mar 4;105(5):822-836.e7. doi: 10.1016/j.neuron.2019.12.004. Epub 2019 Dec 30.

Abstract

Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). GBA1 encodes the lysosomal lipid hydrolase glucocerebrosidase (GCase), and its activity has been linked to accumulation of α-synuclein. The current study systematically examines the relationship between GCase activity and both pathogenic and non-pathogenic forms of α-synuclein in primary hippocampal, cortical, and midbrain neuron and astrocyte cultures, as well as in transgenic mice and a non-transgenic mouse model of PD. We find that reduced GCase activity does not result in aggregation of α-synuclein. However, in the context of extant misfolded α-synuclein, GCase activity modulates neuronal susceptibility to pathology. Furthermore, this modulation does not depend on neuron type but rather is driven by the level of pathological α-synuclein seeds. This study has implications for understanding how GBA1 mutations influence PD pathogenesis and provides a platform for testing novel therapeutics.

摘要

GBA1 基因突变是帕金森病 (PD) 和路易体痴呆 (DLB) 的最常见遗传风险因素。GBA1 编码溶酶体脂质水解酶葡萄糖脑苷脂酶 (GCase),其活性与α-突触核蛋白的积累有关。本研究系统地研究了 GCase 活性与原发性海马、皮质和中脑神经元和星形胶质细胞培养物以及转基因小鼠和非转基因 PD 小鼠模型中致病性和非致病性 α-突触核蛋白之间的关系。我们发现,GCase 活性降低不会导致 α-突触核蛋白聚集。然而,在现存的错误折叠的 α-突触核蛋白的情况下,GCase 活性调节神经元对病理学的易感性。此外,这种调节不依赖于神经元类型,而是由病理性 α-突触核蛋白种子的水平驱动。这项研究对于理解 GBA1 突变如何影响 PD 的发病机制具有重要意义,并为测试新的治疗方法提供了一个平台。

相似文献

1
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Neuron. 2020 Mar 4;105(5):822-836.e7. doi: 10.1016/j.neuron.2019.12.004. Epub 2019 Dec 30.
4
Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.
J Neurosci. 2023 Jan 18;43(3):501-521. doi: 10.1523/JNEUROSCI.0680-22.2022. Epub 2022 Dec 7.
5
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Neurobiol Dis. 2015 Oct;82:495-503. doi: 10.1016/j.nbd.2015.09.009. Epub 2015 Sep 25.
6
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3537-42. doi: 10.1073/pnas.1220464110. Epub 2013 Jan 7.
7
Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Hum Mol Genet. 2018 Jun 1;27(11):1972-1988. doi: 10.1093/hmg/ddy105.
8
Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Antioxid Redox Signal. 2015 Aug 20;23(6):550-64. doi: 10.1089/ars.2015.6307. Epub 2015 Jul 29.
9
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23.

引用本文的文献

1
Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein.
Mol Neurodegener. 2025 Aug 12;20(1):90. doi: 10.1186/s13024-025-00879-0.
2
Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysis.
NPJ Parkinsons Dis. 2025 Aug 2;11(1):226. doi: 10.1038/s41531-025-01060-6.
3
Parkinson's disease: exploring the systemic immune mechanisms through molecular investigations.
Inflammopharmacology. 2025 Jun 23. doi: 10.1007/s10787-025-01816-9.
4
Key Connectomes and Synaptic-Compartment-Specific Risk Genes Drive Pathological α-Synuclein Spreading.
Adv Sci (Weinh). 2025 Jul;12(25):e2413052. doi: 10.1002/advs.202413052. Epub 2025 May 28.
7
Genetic variants associated with idiopathic Parkinson's disease in Latin America: A systematic review.
Neurogenetics. 2025 Apr 3;26(1):43. doi: 10.1007/s10048-025-00817-8.
8
OTUD5 Protects Dopaminergic Neurons by Promoting the Degradation of α-Synuclein in Parkinson's Disease Model.
Adv Sci (Weinh). 2025 Feb;12(7):e2406700. doi: 10.1002/advs.202406700. Epub 2024 Dec 25.
10
Lewy pathology formation in patient-derived GBA1 Parkinson's disease midbrain organoids.
Brain. 2025 Apr 3;148(4):1242-1257. doi: 10.1093/brain/awae365.

本文引用的文献

4
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Acta Neuropathol Commun. 2018 May 31;6(1):45. doi: 10.1186/s40478-018-0550-0.
5
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.
Nature. 2018 May;557(7706):558-563. doi: 10.1038/s41586-018-0104-4. Epub 2018 May 9.
6
Predictive Model of Spread of Progressive Supranuclear Palsy Using Directional Network Diffusion.
Front Neurol. 2017 Dec 21;8:692. doi: 10.3389/fneur.2017.00692. eCollection 2017.
7
GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers.
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):798-803. doi: 10.1073/pnas.1700465115. Epub 2018 Jan 8.
8
Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide.
Neuron. 2018 Jan 3;97(1):92-107.e10. doi: 10.1016/j.neuron.2017.12.012. Epub 2017 Dec 28.
9
Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Mol Genet Metab. 2017 Dec;122(4):198-208. doi: 10.1016/j.ymgme.2017.11.001. Epub 2017 Nov 21.
10
Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
J Neurosci. 2017 Oct 4;37(40):9617-9631. doi: 10.1523/JNEUROSCI.1525-17.2017. Epub 2017 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验